Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for NovAccess Global Inc. (XSNX : OTC)

• Company Description    NovAccess Global Inc. is a biomedical company developing novel immunotherapies for brain tumor patients. NovAccess Global Inc. is based in CLEVELAND, OH. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.00 Daily Weekly Monthly 20 Day Moving Average: 2,824 shares Shares Outstanding: 44.60 (millions) Market Capitalization: $0.01 (millions) Beta: 1.60 52 Week High: $0.01 52 Week Low: $0.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -33.33% -35.08% 12 Week -33.33% -36.10% Year To Date -98.00% -98.25%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 8584 E. WASHINGTON STREET NO. 127 - CHAGRIN FALLS,OH 44023 USA ph: 213-642-9268 fax: 949-266-5823 jdarrow@darrowir.com http://www.novaccessglobal.com

• General Corporate Information    Officers Dwain K. Irvin - Chief Executive Officer John A. Cassarini - Chairman Neil J. Laird - Chief Financial Officer Jason M. Anderson - Director Michael Russak - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 67001N107 SIC: 2834 Fiscal Year Fiscal Year End: September Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 44.60 Most Recent Split Date: 8.00 (0.00:1) Beta: 1.60 Market Capitalization: $0.01 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - - 03/31/25 - - ROA 09/30/25 - - 06/30/25 - - 03/31/25 - - Current Ratio 09/30/25 - - 06/30/25 - - 03/31/25 - - Quick Ratio 09/30/25 - - 06/30/25 - - 03/31/25 - - Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - - 03/31/25 - - Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - -

Powered by Zacks Investment Research ©